Immatics is the global leader in precision targeting of PRAME
PRAME is a protein found inside tumor cells.
We reveal PRAME so it can be targeted.
Targeting
PRAME
could unlock entirely new treatment options
for patients who may need them most.
PRAME is expressed in more than 50 cancers.
We are developing novel immunotherapies to recognize and eliminate cancer cells that present PRAME.
Immatics has the broadest PRAME franchise with the most PRAME indications and modalities.
Our investigational PRAME pipeline includes:
Anzu-cel
(anzutresgene autoleucel, IMA203)
IMA203CD8
IMA402
We are developing two modalities to target PRAME: T-cell receptor (TCR) T-cell therapies and bispecifics.
We decode some of the most complex oncology challenges on earth.
In pursuit of one more hug.
One more ride.
One more life.
Cancer cells survive by staying unseen.
We reveal them.
We fight
so people live
Press releases